Abstracts Archive - Page 766 of 2607 - ACR Meeting Abstracts

Abstract Number: 0913 • ACR Convergence 2021
Long-Term Safety and Efficacy of Certolizumab Pegol in Patients with Active Non‑Radiographic Axial Spondyloarthritis: 3-Year Results from a Phase 3 Multicenter Study
Désirée van der Heijde¹, Lianne Gensler², Walter Maksymowych³, Robert Landewé⁴, Martin Rudwaleit⁵, Lars Bauer⁶, Bengt Hoepken⁶, Thomas Kumke⁶, Mindy Kim⁷ and Atul Deodhar⁸, ¹Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ²Department of Rheumatology, University of California San Francisco, San Francisco, CA, ³Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada, ⁴Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands, ⁵University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁶UCB Pharma, Monheim am Rhein, Germany, ⁷UCB Pharma, Smyrna, GA, ⁸Oregon Health & Science University, Portland, OR
Background/Purpose: Certolizumab pegol (CZP) has demonstrated clinical efficacy in patients with active non-radiographic axial spondyloarthritis (nr-axSpA) and objective signs of inflammation (sacroiliitis on MRI and/or…
Abstract Number: 0914 • ACR Convergence 2021
Response to Certolizumab Pegol in Patients with Non-Radiographic Axial Spondyloarthritis by Baseline C-Reactive Protein Cut-Offs: Post-Hoc Analysis from a Phase 3 Multicenter Study
Philip Robinson¹, Stephen Hall², Bengt Hoepken³, Lars Bauer³, Eleni Demas⁴, Mindy Kim⁵ and Atul Deodhar⁶, ¹University of Queensland School of Clinical Medicine, Brisbane, Queensland, Australia, Herston, Australia, ²Emeritus Research and Monash University, Melbourne, Australia, Melbourne, Australia, ³UCB Pharma, Monheim am Rhein, Germany, ⁴UCB Pharma, Slough, United Kingdom, ⁵UCB Pharma, Smyrna, GA, ⁶Oregon Health & Science University, Portland, OR
Background/Purpose: Certolizumab pegol (CZP), an Fc-free, PEGylated tumor necrosis factor (TNF) inhibitor, has previously demonstrated efficacy and safety in patients with radiographic (r) and non-radiographic…
Abstract Number: 0915 • ACR Convergence 2021
Biomarkers of Extracellular Matrix Turnover Reflect Treatment Response and Pharmacodynamic Effects of TNF-α Inhibitory Therapy in Patients with Axial Spondyloarthritis
Helena Port Linares¹, Signe Holm Nielsen², Peder Frederiksen³, Sofie Falkenløve Madsen⁴, Anne-Christine Bay-Jensen⁵, Morten Karsdal⁵, Inge Juul Sørensen⁶, Bente Jensen⁷, Anne Gitte Loft⁸, Ole Rintek Madsen⁷, Mikkel Ostergaard⁹ and Susanne Pedersen¹⁰, ¹Nordic Bioscience and University of Copenhagen, School of Health and Medical Sciences, Copenhagen, Denmark, ²Nordic Bioscience and Technical University of Denmark, Biomedicine and Biotechnology, Kgs. Lyngby, Herlev, Denmark, ³Nordic Bioscience, Herlev, Copenhagen, Denmark, ⁴University of Copenhagen, School of Health and Medical Sciences, Herlev, Copenhagen, Denmark, ⁵Nordic Bioscience, Herlev, Denmark, ⁶Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark, ⁷Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark, ⁸Aarhus University Hospital, Aarhus, Denmark, ⁹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, and Department of Clinical Medicine, University of Copenhagen, Glostrup, Denmark, ¹⁰Rigshospitalet, Center for Arthritis Research, Glostrup, Denmark
Background/Purpose: Axial spondyloarthritis (axSpA) is a chronic inflammatory disease associated with extracellular matrix (ECM) remodeling of the cartilage, bone, and connective tissues. Quantification of ECM-mediated…
Abstract Number: 0916 • ACR Convergence 2021
Disease Activity and Inflammation in Axial Spondyloarthritis Patients Who Did Not Experience Flares Following Certolizumab Pegol Withdrawal, Dose Reduction or Dose Continuation
Lianne Gensler¹, Xenofon Baraliakos², Lars Bauer³, Bengt Hoepken³, Thomas Kumke³, Mindy Kim⁴ and Robert Landewé⁵, ¹Department of Rheumatology, University of California San Francisco, San Francisco, CA, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ³UCB Pharma, Monheim am Rhein, Germany, ⁴UCB Pharma, Smyrna, GA, ⁵Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands
Background/Purpose: C-OPTIMISE was a phase 3b study investigating certolizumab pegol (CZP) maintenance dose continuation, reduction or withdrawal following achievement of sustained remission in patients with…
Abstract Number: 0917 • ACR Convergence 2021
Efficacy of Secukinumab and HLA-B27 Subtypes: Results from a Phase IIIb Randomised Controlled Trial in Axial SpA
Denis Poddubnyy¹, Effie Pournara², Barbara Schulz², Sanchayita Sadhu³, Atul Deodhar⁴, Xenofon Baraliakos⁵ and Helena Marzo-Ortega⁶, ¹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ²Novartis Pharma AG, Basel, Switzerland, ³Novartis Healthcare Pvt. Ltd, Hyderabad, India, ⁴Oregon Health & Science University, Portland, OR, ⁵Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ⁶NIHR Leeds Biomedical Research Centre and University of Leeds, Leeds, United Kingdom
Background/Purpose: Human Leukocyte Antigen (HLA)-B is strongly associated with axial spondyloarthritis (axSpA); over 100 subtypes of HLA-B27 are currently recognized and designated as HLA-B∗2701 to…
Abstract Number: 0918 • ACR Convergence 2021
Individual Components Contributing to the Achievement of Assessment in SpondyloArthritis International Society 40 Response in Biologic Naïve Patients with Radiographic Axial Spondyloarthritis: Results from the COAST V Trial
Denis Poddubnyy¹, Suzan Mansour Hussein Attar², Michael J. Nissen³, Erica Fillipi⁴, Hagen Russ⁴, Alper Erdogan⁴, Yves Schymura⁴, Soyi Liu-Leage⁵, Eduardo Collantes-Estevez⁶ and Francesco Ciccia⁷, ¹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ²King Abdulaziz University, Jeddah, Saudi Arabia, Jeddah, Saudi Arabia, ³Division of Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁴Eli Lilly and Company Ltd., Indianapolis, IN, ⁵Eli Lilly and Company, Neuilly sur Seine, France, ⁶Department of Rheumatology, Reina Sofia University Hospital/Maimonides Biomedical Research Institute of Cordoba (IMIBIC), University of Cordoba, Cordoba, Spain, ⁷University of Campania “Luigi Vanvitelli", Naples, Italy
Background/Purpose: Ixekizumab (IXE), an IL-17A antagonist, is effective in patients with radiographic axial spondyloarthritis (rad-axSpA). Assessment in SpondyloArthritis International Society (ASAS) 40 response – the…
Abstract Number: 0919 • ACR Convergence 2021
Ixekizumab Shows a Distinct Pattern of Pain Improvement Beyond Measurable Inflammation as Assessed by MRI or CRP or BASDAI Questions 5 & 6 in Patients with Ankylosing Spondylitis
Kurt de Vlam¹, Philip Conaghan², Philip Mease³, Proton Rahman⁴, Venkatesh Krishnan⁵, Rebecca Bolce⁵, David Sandoval Calderon⁵, So Young Park⁵, Gaia Gallo⁵ and Walter Maksymowych⁶, ¹University Hospitals Leuven, Leuven, Belgium, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁴Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁵Eli Lilly and Company, Indianapolis, IN, ⁶Department of Medicine, Division of Rheumatology at the University of Alberta, Alberta, Canada
Background/Purpose: Ixekizumab (IXE) demonstrated rapid efficacy in patients (pts) with AS at week (W) 16 in the absence of elevated inflammation as measured by baseline…
Abstract Number: 0920 • ACR Convergence 2021
Influence of Baseline Demographics on Improvements in Disease Activity Measures in Patients with Ankylosing Spondylitis Receiving Upadacitinib: A Post Hoc Subgroup Analysis
Filip Van den Bosch¹, Denis Poddubnyy², Jayne Stigler³, Andrew Ostor⁴, Salvatore D'Angelo⁵, Victoria Navarro-Compán⁶, In-Ho Song³, Tianming Gao³, Fabiana Ganz³ and Lianne Gensler⁷, ¹Dept. of Rheumatology - Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, ²Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ³AbbVie Inc., North Chicago, IL, ⁴Monash University, Cabrini Hospital, and Emertius Research, Malvern, Australia, ⁵Rheumatology Institute of Lucania (IReL) – Rheumatology Department of Lucania, “San Carlo” Hospital of Potenza and “Madonna delle Grazie” Hospital of Matera, Potenza, Italy, ⁶Rheumatology service, Hospital Universitario La Paz-IdiPaz, Madrid, Spain, ⁷Department of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Upadacitinib (UPA), an oral Janus kinase inhibitor, has demonstrated efficacy and safety through 14 weeks in the SELECT-AXIS 1 study in biologic disease-modifying antirheumatic…
Abstract Number: 0921 • ACR Convergence 2021
Effect of Secukinumab on Radiographic Progression and Inflammation in Sacroiliac Joints and Spine in Patients with Non-radiographic Axial Spondyloarthritis: 2-year Imaging Outcomes from a Phase III Randomized Trial
Juergen Braun¹, Ricardo Blanco², Helena Marzo-Ortega³, Lianne Gensler⁴, Filip Van den Bosch⁵, Stephen Hall⁶, Hideto Kameda⁷, Denis Poddubnyy⁸, Marleen van de Sande⁹, Désirée van der Heijde¹⁰, Tingting Zhuang¹¹, Anna Stefanska¹², Aimee Readie¹¹, Hanno Richards¹³ and Atul Deodhar¹⁴, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Hospital University Marqués de Valdecilla, IDIVAL, Division of Rheumatology, Santander, Spain, ³NIHR Leeds Biomedical Research Centre and University of Leeds, Leeds, United Kingdom, ⁴Department of Rheumatology, University of California San Francisco, San Francisco, CA, ⁵Dept. of Rheumatology - Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, ⁶Emeritus Research and Monash University, Melbourne, Australia, Melbourne, Australia, ⁷Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Toho University, Tokyo, Japan, ⁸Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ⁹Amsterdam UMC, University of Amsterdam, Amsterdam Rheumatology and Immunology Center, Amsterdam, Netherlands, ¹⁰Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ¹¹Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹²Novartis Ireland Limited, Dublin, Ireland, Dublin, Ireland, ¹³Novartis Pharma AG, Basel, Switzerland, ¹⁴Oregon Health & Science University, Portland, OR
Background/Purpose: Axial spondyloarthritis (axSpA) is characterized by inflammation of the sacroiliac joints (SIJ) and the spine. Secukinumab (SEC) treatment was clinically efficacious and reduced SIJ…
Abstract Number: 0922 • ACR Convergence 2021
Bimekizumab Shows Sustained and Meaningful Long-Term Improvements in Health-Related Quality of Life in Ankylosing Spondylitis: Interim Results After 3 Years of Treatment in an Ongoing Phase 2b Study
Atul Deodhar¹, Maxime Dougados², Karl Gaffney³, Raj Sengupta⁴, Marina Magrey⁵, Natasha de Peyrecave⁶, Marga Oortgiesen⁷, Thomas Vaux⁸, Carmen Fleurinck⁶, Vanessa Taieb⁸, Christine de la Loge⁹ and Xenofon Baraliakos¹⁰, ¹Oregon Health & Science University, Portland, OR, ²Université de Paris . Department of Rheumatology - Hôpital Cochin. Assistance Publique - Hôpitaux de Paris . INSERM (U1153): Clinical epidemiology and biostatistics, PRES Sorbonne Paris-Cité. Paris, France., Paris, France, ³Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom, ⁴The Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁵Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, USA, Richfield, OH, ⁶UCB Pharma, Brussels, Belgium, ⁷UCB Pharma, Raleigh, NC, ⁸UCB Pharma, Slough, United Kingdom, ⁹PCOM Analytics, Avallon, France, Avallon, France, ¹⁰Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits both interleukin (IL)-17F and IL-17A, has been demonstrated to be efficacious and well tolerated in…
Abstract Number: 0923 • ACR Convergence 2021
Minimal Impact of the COVID-19 Pandemic on Patient-Reported Disease Activity and Health-Related Quality of Life in Patients with Ankylosing Spondylitis Receiving Bimekizumab: Post Hoc Analyses from a Phase 2b Study
Philip Robinson¹, Pedro Machado², Nigil Haroon³, Lianne Gensler⁴, John Reveille⁵, Vanessa Taieb⁶, Thomas Vaux⁶, Carmen Fleurinck⁷, Marga Oortgiesen⁸, Natasha de Peyrecave⁷ and Atul Deodhar⁹, ¹University of Queensland School of Clinical Medicine, Brisbane, Queensland, Australia, Herston, Australia, ²Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ³Division of Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴Department of Rheumatology, University of California San Francisco, San Francisco, CA, ⁵Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Raleigh, NC, ⁹Oregon Health & Science University, Portland, OR
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that inhibits both interleukin (IL)-17A and IL-17F, has been demonstrated to be efficacious and well tolerated in patients…
Abstract Number: 0924 • ACR Convergence 2021
Efficacy and Safety of Upadacitinib in Patients with Active Ankylosing Spondylitis: 2-Year Results from a Randomized, Double-Blind, Placebo-Controlled Study with Open-Label Extension
Désirée van der Heijde¹, Atul Deodhar², Walter Maksymowych³, Joachim Sieper⁴, Filip Van den Bosch⁵, Tae-Hwan Kim⁶, Mitsumasa Kishimoto⁷, Andrew Ostor⁸, Bernard Combe⁹, Yunxia Sui¹⁰, Yuanyuan Duan¹¹, Alvina D. Chu¹¹ and In-Ho Song¹², ¹Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ²Oregon Health & Science University, Portland, OR, ³Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada, ⁴Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵Dept. of Rheumatology - Ghent University Hospital, Ghent, Belgium, Ghent, Belgium, ⁶Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ⁷Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁸Monash University, Cabrini Hospital, and Emertius Research, Malvern, Australia, ⁹Montpellier University, Montpellier, France, ¹⁰AbbVie, North Chicago, IL, ¹¹AbbVie Inc, North Chicago, ¹²AbbVie Inc., North Chicago, IL
Background/Purpose: The objective of this long-term analysis of the SELECT-AXIS 1 study was to report safety and efficacy of upadacitinib (UPA) in active AS through…
Abstract Number: 0925 • ACR Convergence 2021
Impact of Achieving ASDAS LDA on Disease Activity and Patient-Reported Outcome Measures Among Patients with Ankylosing Spondylitis Treated with Biologic DMARDs
Philip Mease¹, Robert McLean², Taylor Blachley², Maya Marchese², Laura Anatale-Tardiff³, Christopher Saffore⁴, Danny Quach⁵, Ana Biljan⁶ and Alexis Ogdie⁷, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²CorEvitas, LLC, Waltham, MA, ³CorEvitas, Waltham, MA, ⁴AbbVie, North Chicago, IL, ⁵AbbVie Inc., North Chicago, IL, ⁶Abbvie Inc., Chicago, IL, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: Although Ankylosing Spondylitis Disease Activity Score (ASDAS) low disease activity (LDA) is a common treatment target for disease control when managing AS, real-world research…
Abstract Number: 0926 • ACR Convergence 2021
Predictors of 1-Year Treatment Response Among Upadacitinib-Treated Patients with Ankylosing Spondylitis: A Post Hoc Analysis
Marina Magrey¹, Sofia Ramiro², Marcelo Medeiros Pinheiro³, Tianming Gao⁴, Fabiana Ganz⁴, In-Ho Song⁴, Ana Biljan⁵, Nigil Haroon⁶ and Martin Rudwaleit⁷, ¹Case Western Reserve University, MetroHealth Medical Center, Cleveland, OH, USA, Richfield, OH, ²Leiden University Medical Center, Leiden, Netherlands, ³Universidade Federal de São Paulo, São Paulo, Brazil, ⁴AbbVie Inc., North Chicago, IL, ⁵Abbvie Inc., Chicago, IL, ⁶Division of Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁷University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany
Background/Purpose: Upadacitinib (UPA) is an oral Janus kinase inhibitor that has demonstrated efficacy and safety among patients with ankylosing spondylitis (AS) in the phase 2/3…
Abstract Number: 0927 • ACR Convergence 2021
Whole Blood Transcriptional Changes Following Treatment with Filgotinib in Patients with Ankylosing Spondylitis
Denis Poddubnyy¹, Yihua Liu², William Barchuk³, Robin Besuyen⁴, René Galien⁵, Yuan Tian², Vlad Malkov² and Angie Hertz², ¹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ²Gilead Sciences, Foster City, CA, ³Gilead Sciences, Inc., Foster City, CA, ⁴Galapagos BV, Leiden, Netherlands, ⁵Galapagos NV, Romainvulle, France
Background/Purpose: Ankylosing spondylitis (AS) – also referred to as radiographic axial spondyloarthritis – is a chronic inflammatory disease that affects the sacroiliac joints and spine.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].